IL4 and atopic eczema: Th2 diseases associated with the activation of Type 2 immunity and mediated by IL-4/IL1-13, such as allergic asthma and atopic dermatitis, have been treated with biologic drugs blocking IL-4 [184,185]; these agents target and switch off Th2-induced inflammation.